These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17658575)

  • 1. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.
    Hu Q; Mahmood N; Shattock RJ
    Virology; 2007 Nov; 368(1):145-54. PubMed ID: 17658575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
    Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
    J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.
    Balzarini J; Van Laethem K; Peumans WJ; Van Damme EJ; Bolmstedt A; Gago F; Schols D
    J Virol; 2006 Sep; 80(17):8411-21. PubMed ID: 16912292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin.
    Huang X; Jin W; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2011 Oct; 92(Pt 10):2367-2373. PubMed ID: 21715597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
    Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
    Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.
    Alexandre KB; Moore PL; Nonyane M; Gray ES; Ranchobe N; Chakauya E; McMahon JB; O'Keefe BR; Chikwamba R; Morris L
    Virology; 2013 Nov; 446(1-2):66-76. PubMed ID: 24074568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.
    Alexandre KB; Gray ES; Lambson BE; Moore PL; Choge IA; Mlisana K; Karim SS; McMahon J; O'Keefe B; Chikwamba R; Morris L
    Virology; 2010 Jun; 402(1):187-96. PubMed ID: 20392471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner.
    Bolmstedt AJ; O'Keefe BR; Shenoy SR; McMahon JB; Boyd MR
    Mol Pharmacol; 2001 May; 59(5):949-54. PubMed ID: 11306674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.
    Balzarini J; Van Laethem K; Hatse S; Vermeire K; De Clercq E; Peumans W; Van Damme E; Vandamme AM; Bölmstedt A; Schols D
    J Virol; 2004 Oct; 78(19):10617-27. PubMed ID: 15367629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV.
    Balzarini J
    Lancet Infect Dis; 2005 Nov; 5(11):726-31. PubMed ID: 16253890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview.
    Férir G; Gordts SC; Schols D
    Molecules; 2014 Dec; 19(12):21085-112. PubMed ID: 25517345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitness.
    Mathys L; Balzarini J
    J Antimicrob Chemother; 2014 Mar; 69(3):582-93. PubMed ID: 24144923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120.
    Hoorelbeke B; van Montfort T; Xue J; LiWang PJ; Tanaka H; Igarashi Y; Van Damme EJ; Sanders RW; Balzarini J
    FEBS Lett; 2013 Apr; 587(7):860-6. PubMed ID: 23454641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.